Advances In™: Meeting Unmet Clinical Needs in AML with Evolving Therapeutic Approaches
View More
ACCC 40th National Oncology Conference Pre-Session: Clinical Updates from Chicago – A Focus on What Community Centers Need to Know to Move Their Solid Tumors' Practices Forward
Register Now!
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Antibody-Drug Conjugates in Gynecological Cancer – Setting the Stage
View More
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC
View More
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
Register Now!
Advances In™ Pediatric Neuroblastoma: Exploring Current and Emerging Therapeutic Approaches for Relapsed/Refractory Disease and CNS Metastases
View More
Daratumumab Combos Are Effective in NDMM Despite Relapses in Subgroups
APOBEC mutational activity appears to be prognostic in patients with newly diagnosed multiple myeloma or precursor diseases who receive daratumumab quadruplets, according to Kylee Maclachlan, MBChB, PhD.
Real-world Teclistamab Use Finds Comparable Efficacy With MajesTec-1 in Multiple Myeloma
September 29th 2023When teclistamab was evaluated in a real-world setting, investigators determined that efficacy was similar between that and the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.
Data Confirm Dara-KRd/Double Transplant Benefit in Newly Diagnosed Myeloma
September 29th 2023Investigators report a low rate of high-grade hematologic adverse effects following treatment with induction Dara-KRd and consolidation double transplant in patients with high-risk, newly diagnosed multiple myeloma.
FDA Clears Chromogranin A Immunoassay in Gastroenteropancreatic NETs
Clearance of an automated immunoassay allows practices to measure chromogranin A concentration in human serum, thereby tracking disease progression in those with gastroenteropancreatic neuroendocrine tumors.
Pembrolizumab Combos Miss Survival End Points in Metastatic NSCLC
Pembrolizumab plus lenvatinib does not improve objective response rate compared with standard-of-care treatment among patients with metastatic non–small cell lung cancer in the phase 3 LEAP-006 and LEAP-008 trials.
Longer Surgery Delay After CRT Does Not Improve Esophageal Cancer Responses
Data from the NeoRes II trial caution against routinely delaying surgery for more than 6 weeks after patients with resectable locally advanced esophageal cancer receive neoadjuvant chemoradiotherapy.
Ibrutinib Reduces Risk of Next Treatment Initiation Vs CIT in CLL/SLL
Treatment with ibrutinib significantly reduces the risk of initiating next treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared with bendamustine/rituximab in a real-world setting.
Ribociclib/Aromatase Inhibitors Maintain HRQOL in HR+, HER2– Breast Cancer
A health-related quality of life analysis of the phase 3 NATALEE trial supports the risk/benefit profile of adding ribociclib to nonsteroidal aromatase inhibitors in patients with hormone receptor–positive, HER2-negative early breast cancer.